Share on StockTwits

Insys Therapeutics (NASDAQ:INSY) set a new 52-week high during mid-day trading on Friday, ARN reports. The stock traded as high as $54.30 and last traded at $53.89, with a volume of 236,595 shares. The stock had previously closed at $50.19.

A number of analysts have recently weighed in on INSY shares. Analysts at Zacks downgraded shares of Insys Therapeutics from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, November 19th. They now have a $49.00 price target on the stock. Analysts at JMP Securities raised their price target on shares of Insys Therapeutics from $30.00 to $50.00 in a research note to investors on Tuesday, November 12th. They now have a “market outperform” rating on the stock.

In other Insys Therapeutics news, CFO Darryl Baker unloaded 10,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $49.61, for a total transaction of $496,100.00. Following the completion of the sale, the chief financial officer now directly owns 3,125 shares in the company, valued at approximately $155,031. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Insys Therapeutics has a 52-week low of $7.10 and a 52-week high of $53.64. The stock has a 50-day moving average of $42.58 and a 200-day moving average of $33.89. The company has a market cap of $1.156 billion and a price-to-earnings ratio of 10.35.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.25. The company had revenue of $29.20 million for the quarter, compared to the consensus estimate of $27.00 million. During the same quarter last year, the company posted ($0.32) earnings per share. Insys Therapeutics’s revenue was up 508.3% compared to the same quarter last year. On average, analysts predict that Insys Therapeutics will post $1.33 earnings per share for the current fiscal year.

Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.